This Multibagger Micro-Cap Stock Gains 303 Per cent in a Year: The Company Acquires 51 Per cent Stake in Ishwari Healthcare for Rs 1.50 Crore
The stock has delivered a one-year return of 303.41 per cent.
Sudarshan Pharma Industries Limited has successfully acquired 2,09,100 equity shares of Ishwari Healthcare Private Limited, marking a significant strategic expansion. This acquisition, initially announced on October 14, 2024, was finalised at a revised consideration of Rs 1.50 crore, down from the previously agreed Rs 2.60 crore.
The acquisition grants Sudarshan Pharma a 51 per cent stake in Ishwari Healthcare, effectively making it a subsidiary from April 1, 2025. This move aligns with Sudarshan Pharma's broader strategy to enhance its footprint in the pharmaceutical sector, focusing on manufacturing and trading in chemicals and solvents. The company is also expanding its product offerings and geographical reach, with plans to introduce new pharmaceutical products and enter new international markets. This acquisition is expected to bolster Sudarshan Pharma's capabilities and market presence, reinforcing its commitment to growth and innovation in the pharmaceutical industry.
DSIJ's 'Value Pick' service recommends long-term stocks based on Value Investing Philosophy. If this interests you, do download the service details here.
Sudarshan Pharma Industries Ltd, established in 2008, is engaged in the manufacturing of Active Pharmaceutical Ingredients (API) and pharmaceutical items, alongside trading in chemicals and solvents. The company operates in both domestic and international markets, with a significant presence in Maharashtra, Gujarat, Himachal Pradesh, and Uttarakhand, and exports to regions including the UK, Australia, and the MENA region.
Sudarshan Pharma's product portfolio includes specialty chemicals and a range of branded pharmaceutical products. The company is actively expanding its manufacturing capabilities, with new units set up to produce critical APIs and pharmaceutical formulations. It is also focusing on introducing innovative products such as cardiac first aid kits and new drug delivery systems. Sudarshan Pharma has received approval under the PLI scheme to promote domestic manufacturing of key pharmaceutical ingredients, with substantial investments committed to new projects.
The company's strategic priorities include expanding its product range and entering new international markets, supported by recent acquisitions and the establishment of new subsidiaries.
As of April 3, 2025, the current stock price of Sudarshan Pharma Industries Limited is Rs 31.99. The stock's 52-week high is Rs 51.83, and the 52-week low is Rs 6.31. Sudarshan Pharma Industries Limited has a market capitalisation of Rs 764 crore. The stock has delivered a one-year return of 303.41 per cent. The Price-Earnings (PE) Ratio stands at 65.99. The major public shareholder is Bishwanath Prasad Agrawal, holding 1.70 per cent of the shares.
Investors must keep this micro-cap stock on their radar.
Disclaimer: The article is for informational purposes only and not investment advice.